Kymera Therapeutics Stock: A First Take (NASDAQ:KYMR) TOPICS:Fashion Posted By: Advance February 28, 2022 Share on FacebookShare on TwitterShare on Pinterest Kymera Therapeutics has one asset undergoing evaluation in a Phase 1 study and another two molecules about ready to enter the clinic. Read more about KYMR here.